Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
sodium increased » soil increased (Expand Search), showing increased (Expand Search), codes increased (Expand Search)
point decrease » point increase (Expand Search)
Showing 1 - 17 results of 17 for search '(( significant decrease decrease ) OR ( significant ((point decrease) OR (sodium increased)) ))~', query time: 0.66s Refine Results
  1. 1
    High-Precision Surface Tension Measurements of Sodium, Potassium, and Their Alloys via Du Noüy Ring Tensiometry

    High-Precision Surface Tension Measurements of Sodium, Potassium, and Their Alloys via Du Noüy Ring Tensiometry by Naiyu Qi (21155536)

    Published 2025
    “…The development of post-lithium-ion batteries has sparked significant interest in alkali-metal anodes, particularly sodium (Na), potassium (K), and sodium–potassium (Na–K) alloys. …”
    Save to List
    Saved in:
  2. 2
    Vitamin D3, but not the Cisplatin, could moderately reduce STZ-induced hyperglycemia in mice (a) Schematic representation of experimental protocol followed in the study: After acclimatization, mice were administered with STZ (2 X 30 mg/kg and 2 X 40 mg/kg) to induce hyperglycemia.

    Vitamin D3, but not the Cisplatin, could moderately reduce STZ-induced hyperglycemia in mice (a) Schematic representation of experimental protocol followed in the study: After accl... by Vidya G. Bettada (22208808)

    Published 2025
    “…The data showed a significant increase in fasting blood glucose (FBG) beginning from day 6. …”
    Save to List
    Saved in:
  3. 3
    Table 1_The relationship between dietary sodium intake and all-cause mortality in patients with non-alcoholic fatty liver disease: a cohort study from NHANES 2003–2018.docx

    Table 1_The relationship between dietary sodium intake and all-cause mortality in patients with non-alcoholic fatty liver disease: a cohort study from NHANES 2003–2018.docx by Jiajun Li (1410187)

    Published 2025
    “…Smooth curve fitting and threshold analysis revealed a non-linear association between sodium intake and NAFLD risk, with an inflection point at 2.49 g/d, above which NAFLD risk significantly increased. …”
    Save to List
    Saved in:
  4. 4
    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  5. 5
    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  6. 6
    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  7. 7
    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  8. 8
    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  9. 9
    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  10. 10
    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  11. 11
    Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  12. 12
    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  13. 13
    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  14. 14
    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  15. 15
    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.pdf

    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
    Save to List
    Saved in:
  16. 16
    Differential neural dynamics in the GNP model incorporating electrodiffusion and ion concentration changes.

    Differential neural dynamics in the GNP model incorporating electrodiffusion and ion concentration changes. by Zichao Liu (4591993)

    Published 2025
    “…(f) The harmonic means of intramembrane potassium and chloride concentrations increase, whereas for sodium, it decreases during neural activity. …”
    Save to List
    Saved in:
  17. 17
    Update on trimethylamine N-oxide (TMAO) as a piezolyte and cryoprotectant: its role in a depth limit for marine fishes and loss from hadal fish during capture

    Update on trimethylamine N-oxide (TMAO) as a piezolyte and cryoprotectant: its role in a depth limit for marine fishes and loss from hadal fish during capture by Paul Yancey (14354982)

    Published 2025
    “…Except for teleosts (see below), these animals are osmoconformers, such that as TMAO increases with depth, other osmolytes must decrease (e.g., urea in elasmobranchs as noted above). …”
    Save to List
    Saved in:

Search Tools: